-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47

Benzinga·10/15/2026 14:38:02
Listen to the news
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.